Loading...
25 acetaminophen COVID-19 controlled studies, 2 RCTs
https://c19early.org/acemeta.html
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+ Rinott -473% 5.73 [0.30-109] death 3/85 0/49 OT1 Improvement, RR [CI] Treatment Control Rinott -534% 6.34 [0.84-47.6] oxygen 11/85 1/49 OT1 Lapi (ES) -15% 1.15 [0.92-1.43] death/hosp. n/a n/a Lapi (ES) -29% 1.29 [0.61-2.73] death/hosp. n/a n/a Sharif -77% 1.77 [0.39-8.09] death 9/361 2/142 Manjani -220% 3.20 [1.51-6.82] death 64/388 7/136 Manjani -434% 5.34 [1.98-14.4] ventilation 388 (n) 136 (n) Manjani -244% 3.44 [1.49-8.54] progression 132 (n) 136 (n) Manjani -201% 3.01 [1.40-7.07] progression 256 (n) 136 (n) Manjani -100% 2.00 [1.33-3.02] hosp. time 388 (n) 136 (n) Lerner -27% 1.27 [0.96-1.68] death 5,783 (all patients) Ravichandran (RCT) -43% 1.43 [1.14-1.78] no recov. 77/107 52/103 OT1 Ravichandran (RCT) -3925% 40.25 [2.47-657] progression 20/107 0/103 OT1 Ravichandran (RCT) -133% 2.33 [1.82-3.00] recov. time 107 (n) 103 (n) OT1 Ravichandran (RCT) -75% 1.75 [1.48-2.06] recov. time 107 (n) 103 (n) OT1 Ravichandran (RCT) -75% 1.75 [1.48-2.06] recov. time 107 (n) 103 (n) OT1 Ravichandran (RCT) -20% 1.20 [0.93-1.56] viral+ 43/60 37/62 OT1 Lapi -75% 1.75 [1.40-2.18] death/hosp. n/a n/a Abolhassani -56% 1.56 [0.58-4.18] death 3/6 8/25 Baldia (ICU) 12% 0.88 [0.72-1.07] death 1,166 (n) 1,480 (n) ICU patients Baldia (ICU) 14% 0.86 [0.72-1.03] death 1,166 (n) 1,480 (n) ICU patients Stufano -19% 1.19 [0.70-2.02] PASC 11/23 23/57 Sobhy (DB RCT) -110% 2.10 [1.05-4.20] ICU 21/90 10/90 OT1 Sobhy (DB RCT) -110% 2.10 [1.05-4.20] oxygen 21/90 10/90 OT1 Sobhy (DB RCT) -36% 1.36 [1.07-1.73] hosp. time 90 (n) 90 (n) OT1 Sobhy (DB RCT) -33% 1.33 [0.31-5.79] no recov. 4/90 3/90 OT1 Sobhy (DB RCT) -75% 1.75 [0.77-3.97] no recov. 14/90 8/90 OT1 Sobhy (DB RCT) -92% 1.92 [1.05-3.52] no recov. 25/90 13/90 OT1 Sobhy (DB RCT) -70% 1.70 [1.06-2.72] no recov. 34/90 20/90 OT1 Blanc -51% 1.51 [0.82-2.84] cases 60 (n) 119 (n) Kolin -23% 1.23 [1.05-1.43] cases 397,064 (all patients) Park (PSM) 25% 0.75 [0.35-1.59] death 12/397 16/397 OT1 Park (PSM) 38% 0.62 [0.19-1.89] ventilation 5/397 8/397 OT1 Gálvez-Barrón -47% 1.47 [0.66-3.33] death 43 (n) 60 (n) Gálvez-Barrón 23% 0.77 [0.35-1.71] severe case 43 (n) 60 (n) Reese (PSM) -61% 1.61 [1.40-1.84] death 20,826 (n) 20,826 (n) Reese (PSM) -816% 9.16 [8.72-9.63] severe case 20,826 (n) 20,826 (n) Chandan (PSM) -18% 1.18 [0.83-1.64] death 71/8,595 79/8,595 OT1 CT2 Chandan (PSM) -27% 1.27 [0.90-1.75] cases 8,595 (n) 8,595 (n) OT1 CT2 Oh 2% 0.98 [0.38-2.49] death 58 (n) 7,655 (n) Leal 7% 0.93 [0.91-0.96] cases n/a n/a Moreno-Martos -29% 1.29 [1.27-1.32] hosp. Moreno-Martos -52% 1.52 [1.28-1.79] hosp. 103/178 196/514 Moreno-Martos -5% 1.05 [0.91-1.22] hosp. 87/144 360/626 Moreno-Martos 22% 0.78 [0.63-0.98] hosp. 64/319 1,585/6,181 Moreno-Martos -16% 1.16 [1.13-1.20] hosp. Moreno-Martos -57% 1.57 [1.50-1.65] hosp. 1,090/1,868 3,414/9,188 Moreno-Martos -47% 1.47 [1.40-1.54] hosp. 1,397/2,875 3,214/9,735 MacFadden -48% 1.48 [1.44-1.51] cases n/a n/a Campbell (PSW) -1% 1.01 [0.99-1.02] death 2,074 (n) 20,311 (n) Campbell (PSW) 0% 1.00 [0.99-1.02] death 2,074 (n) 20,311 (n) Xie -5% 1.05 [0.70-1.56] hosp. population-based cohort OT1 Xie 3% 0.97 [0.72-1.29] cases population-based cohort OT1 Kim (PSM) -71% 1.71 [0.69-4.24] death 12/162 7/162 OT1 Kim (PSM) -14% 1.14 [0.42-3.08] ventilation 8/162 7/162 OT1 Kim (PSM) 40% 0.60 [0.15-2.47] ICU 3/162 5/162 OT1 Kim (PSM) -9% 1.09 [0.64-1.86] oxygen 24/162 22/162 OT1 Ritsinger -21% 1.21 [1.17-1.25] death 24,641 (n) 20,225 (n) Acetaminophen COVID-19 outcomes c19 earlyOctober 2023 1 OT: comparison with other treatment 2 CT: study uses combined treatment Favors acetaminophen Favors control
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit
